Frost and Sullivan presents its 2004 Product line innovation award to Bruker Daltonics for its innovative development of sophisticated mass spectrometers
Frost and Sullivan has selected Bruker Daltonics for its 2004 product line innovation award for the life sciences.
Frost and Sullivan analyst Sinead Igoe stated: "Bruker Daltonics has received this award for its innovative development of sophisticated mass spectrometers.
"Concentrating on meeting the needs of life science researchers, Bruker Daltonics aids the researchers in overcoming complex challenges encountered in their life science research, especially in the proteomics field. "Bruker Daltonics offers innovative, high quality solutions that support all life science applications from genomics through to clinical proteomics.
"Bruker Daltonics offers a suite of sophisticated mass spectrometers providing researchers the option of various solutions from a trusted manufacturer".
Frost and Sullivan manager Manoj Kenkare added: "Bruker Daltonics recognises the changing needs of researchers involved in the life science market and responds with enhanced capabilities. "Experiencing great adoption and acceptance of its life science mass spectrometers, the company continues to enjoy revenue growth, demonstrated by a 29% increase in revenues in 2003 over 2002.
"A leader in the life science mass spectrometry space, Bruker Daltonics is positioned to continue growth and success.
"Bruker Daltonics focuses on providing highly innovative and advanced solutions to the life science researchers to generate the highest quality and information-rich analyses.
"This aim of meeting researchers' needs and providing innovative, top-of-the-line solutions to create highly sophisticated product lines warrants Bruker Daltonics' receiving Frost and Sullivan's 2004 product line innovation award".
Frank Laukien, president and CEO of Bruker Daltonics, commented: "We are very gratified by this award, and pleased to have been recognised by Frost and Sullivan for the fourth time in three years for our innovation and growth strategy in the life sciences."
